Supp Figure S3 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Figure S3. AFP response cutoff determination for overall survival by maximally selected rank statistics. Cutpoint determination plots showing (A) histogram distribution and (B) rank statistic plot of percent AFP change from baseline at Week 8 for patients in the cabozantinib group with baseline AFP {greater than or equal to}20 ng/mL. *Calculated value of 0.48%, rounded to 0% for all subsequent analyses.